Clinical Trial Packaging Market - Forecasts from 2020 to 2025
The clinical trials packaging market is projected to grow at a CAGR of 4.41% to reach US$1.482 billion by 2025. The increasing importance of proper packaging techniques in order to preserve the quality of the medicines for clinical trials and the presence of the stringent guidelines is leading to market players providing effective and enhanced clinical trial packing solutions and services to end-users.
As there been an increase in the number of orphan diseases or rare diseases which is affecting the population throughout the world, there has been a surge in the number of clinical trials that are being carried out worldwide. According to that statistics by U.S. National Library OF Medicine, there are about 165,436 or 49% of the clinal studies and research being conducted in Non-U.S. locations, 112,905 or 34% have been conducted in the U.S. only, 17,369 or 5% have been conducted in both U.S. and Non-U.S. locations. Lastly, the data for 39,492 or 12% of clinical trials in other locations has not been reported. This is calling for medicine mand pharmaceutical manufacturers to come up with better formulations and effective compositions in order to control these diseases effectively. Consequently, it is putting a burden on the clinical trial packing companies and players to improve the state and the quality of their packing solutions as there is critical issue involved in the packaging and of sensitive drugs for the clinical trials.
In addition, there are 4 phases in clinical trials, Phase I – Phase IV. Each phase requires a stringent packaging requirement. In Phase 1 only a limited number of packs are sent so packaging, which is called the primary packaging that must be good enough as the shelf life of the testing medicine is not much. More importantly, the secondary packing includes proper labeling, which should contain the manufacturer's name, the medicine name and its components with its shelf life, warnings and content hazards and some measures need to use to prevent counterfeiting and tampering. Then the primary packaged medicine, which is done suing cold form or thermoform techniques, is out inside the secondary package such as bottles, kits or others with effective temperature control. Therefore, this has led to an increase in the demand for effective packing solutions by the market players and is a major driving factor in the market growth over the forecast period.
Product Launches by Major Market Players
The better, advanced and diverse varieties of clinical trials packaging with enhanced features that are able to effectively aid in the proper and efficient crop production. These products are being launched by existing and new players in different markets is estimated to lead to increased adoption and propel the market growth further over the forecast period.
Recent Developments
The North American region is expected to hold a significant share over the forecast period, which is attributable to the fact that the pharmaceutical and packing industry In the US is flourishing and due to the increasing influx pf investments. In addition, there are stringent guidelines in place for the packaging of the medicine to be used for clinical trials by organizations such as FDA that must be complied with by the market players in order to minimize their losses and avoid the imposition of heavy penalties.
Segmentation:
As there been an increase in the number of orphan diseases or rare diseases which is affecting the population throughout the world, there has been a surge in the number of clinical trials that are being carried out worldwide. According to that statistics by U.S. National Library OF Medicine, there are about 165,436 or 49% of the clinal studies and research being conducted in Non-U.S. locations, 112,905 or 34% have been conducted in the U.S. only, 17,369 or 5% have been conducted in both U.S. and Non-U.S. locations. Lastly, the data for 39,492 or 12% of clinical trials in other locations has not been reported. This is calling for medicine mand pharmaceutical manufacturers to come up with better formulations and effective compositions in order to control these diseases effectively. Consequently, it is putting a burden on the clinical trial packing companies and players to improve the state and the quality of their packing solutions as there is critical issue involved in the packaging and of sensitive drugs for the clinical trials.
In addition, there are 4 phases in clinical trials, Phase I – Phase IV. Each phase requires a stringent packaging requirement. In Phase 1 only a limited number of packs are sent so packaging, which is called the primary packaging that must be good enough as the shelf life of the testing medicine is not much. More importantly, the secondary packing includes proper labeling, which should contain the manufacturer's name, the medicine name and its components with its shelf life, warnings and content hazards and some measures need to use to prevent counterfeiting and tampering. Then the primary packaged medicine, which is done suing cold form or thermoform techniques, is out inside the secondary package such as bottles, kits or others with effective temperature control. Therefore, this has led to an increase in the demand for effective packing solutions by the market players and is a major driving factor in the market growth over the forecast period.
Product Launches by Major Market Players
The better, advanced and diverse varieties of clinical trials packaging with enhanced features that are able to effectively aid in the proper and efficient crop production. These products are being launched by existing and new players in different markets is estimated to lead to increased adoption and propel the market growth further over the forecast period.
Recent Developments
- In February 2020, Almac Clinical Services, which is a member of the Almac Group, one of the leading companies that is involved in the provision of pharmaceutical development and manufacturing solutions announced that launch if its new solution called the “Label Approval Solution (LAS)”. It is a fully compliant and vigilant system developed in order to manage the clinical labels effectively to adhere to the protocols. The LAS solution is aimed towards enabling the sponsors to gain access to the latest, upcoming technology, and thereby streamlining review and the approval label proofs, master text production, and label text localization. In addition, the solution is also able to provide and optimize all the clinical label development processes via supporting the centralized technology LAS
- In January 2019, PCI Services, one of the leading companies dealing in the provision of pharmaceutical services including development, and supply announced an additional investment in there in order to expand their infrastructure for substance storage and packaging. This was done in order to improve their capacity for their blister packing segment, which is increasingly essential in dispensing opioid prescription drugs for clinical trials in being a limited quantity unit dose packaging as an approach in order to effectively and properly combat substance abuse. The facility that was expanded is situated as their commercial packing locations in Philadelphia, PA U.S. and Rockford, IL U.S. and will undertake more and more expansion as the demand for specialize medicines increases. In addition, the company is also in support of the DEA Schedule I-V controlled susbtsaabced act for the commercial medicines available on prescription as well those on Investigational clinical trials. In conjunction, the unit dose blister packaging will be child-resistant and a key focus will be kept on the reform measure for the use of opioids in the US.
- In August 2019, August Faller, one of the leading companies dealing in the provision of announced that has improved its product offering by the launch of pharmaceutical and medicine packaging with Russian crypto codes. This has been done in order to increase the safety of the medicines and prevent the misuse and is going to be mandatory on all the pharmaceutical products in the Russian market from January 1, 2020. In addition, August Faller also announced that it has expanded its manufacturing capabilities including the printing of Russian crypto codes on all their cartons and labels.
The North American region is expected to hold a significant share over the forecast period, which is attributable to the fact that the pharmaceutical and packing industry In the US is flourishing and due to the increasing influx pf investments. In addition, there are stringent guidelines in place for the packaging of the medicine to be used for clinical trials by organizations such as FDA that must be complied with by the market players in order to minimize their losses and avoid the imposition of heavy penalties.
Segmentation:
- By Product Type
- Vials
- Blisters
- Tubes
- Bottles
- Bags and Pouches
- Others
- By Material Type
- Plastic
- Glass
- Metal
- Paper
- By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- UK
- Germany
- France
- Spain
- Others
- Middle East and Africa
- Asia Pacific
- Japan
- China
- India
- Others
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. CLINICAL TRIALS PACKAGING MARKET ANALYSIS, BY PRODUCT TYPE
5.1. Introduction
5.2. Vials
5.3. Blisters
5.4. Tubes
5.5. Bottles
5.6. Bags and Pouches
5.7. Others
6. CLINICAL TRIALS PACKAGING MARKET ANALYSIS, BY MATERIAL TYPE
6.1. Introduction
6.2. Plastic
6.3. Glass
6.4. Metal
6.5. Paper
7. CLINICAL TRIALS PACKAGING MARKET ANALYSIS, BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. North America Clinical Trials Packaging Market, By Product Type
7.2.2. North America Clinical Trials Packaging Market, By Material Type
7.2.3. By Country
7.2.3.1. United States
7.2.3.2. Canada
7.2.3.3. Mexico
7.3. South America
7.3.1. South America Clinical Trials Packaging Market, By Product Type
7.3.2. South America Clinical Trials Packaging Market, By Material Type
7.3.3. By Country
7.3.3.1. Brazil
7.3.3.2. Argentina
7.3.3.3. Others
7.4. Europe
7.4.1. Europe Clinical Trials Packaging Market, By Product Type
7.4.2. Europe Clinical Trials Packaging Market, By Material Type
7.4.3. By Country
7.4.3.1. UK
7.4.3.2. Germany
7.4.3.3. France
7.4.3.4. Spain
7.4.3.5. Others
7.5. Middle East and Africa
7.5.1. Middle East and Africa Clinical Trials Packaging Market, By Product Type
7.5.2. Middle East and Africa Clinical Trials Packaging Market, By Material Type
7.6. Asia Pacific
7.6.1. Asia Pacific Clinical Trials Packaging Market, By Product Type
7.6.2. Asia Pacific Clinical Trials Packaging Market, By Material Type
7.6.3. By Country
7.6.3.1. Japan
7.6.3.2. China
7.6.3.3. India
7.6.3.4. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. COMPANY PROFILES
9.1. Piramal Pharma Solutions
9.2. Almac Group
9.3. Fisher Clinical Services, Inc.
9.4. CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC.
9.5. Xerimis
9.6. PCI Services
9.7. Quay Pharma
9.8. Bilcare Ltd
9.9. August Faller GmbH & Co. KG
9.10. Lonza Group Ltd.
9.11. Rhenochem AG
9.12. Mikart, LLC
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. CLINICAL TRIALS PACKAGING MARKET ANALYSIS, BY PRODUCT TYPE
5.1. Introduction
5.2. Vials
5.3. Blisters
5.4. Tubes
5.5. Bottles
5.6. Bags and Pouches
5.7. Others
6. CLINICAL TRIALS PACKAGING MARKET ANALYSIS, BY MATERIAL TYPE
6.1. Introduction
6.2. Plastic
6.3. Glass
6.4. Metal
6.5. Paper
7. CLINICAL TRIALS PACKAGING MARKET ANALYSIS, BY GEOGRAPHY
7.1. Introduction
7.2. North America
7.2.1. North America Clinical Trials Packaging Market, By Product Type
7.2.2. North America Clinical Trials Packaging Market, By Material Type
7.2.3. By Country
7.2.3.1. United States
7.2.3.2. Canada
7.2.3.3. Mexico
7.3. South America
7.3.1. South America Clinical Trials Packaging Market, By Product Type
7.3.2. South America Clinical Trials Packaging Market, By Material Type
7.3.3. By Country
7.3.3.1. Brazil
7.3.3.2. Argentina
7.3.3.3. Others
7.4. Europe
7.4.1. Europe Clinical Trials Packaging Market, By Product Type
7.4.2. Europe Clinical Trials Packaging Market, By Material Type
7.4.3. By Country
7.4.3.1. UK
7.4.3.2. Germany
7.4.3.3. France
7.4.3.4. Spain
7.4.3.5. Others
7.5. Middle East and Africa
7.5.1. Middle East and Africa Clinical Trials Packaging Market, By Product Type
7.5.2. Middle East and Africa Clinical Trials Packaging Market, By Material Type
7.6. Asia Pacific
7.6.1. Asia Pacific Clinical Trials Packaging Market, By Product Type
7.6.2. Asia Pacific Clinical Trials Packaging Market, By Material Type
7.6.3. By Country
7.6.3.1. Japan
7.6.3.2. China
7.6.3.3. India
7.6.3.4. Others
8. COMPETITIVE ENVIRONMENT AND ANALYSIS
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. COMPANY PROFILES
9.1. Piramal Pharma Solutions
9.2. Almac Group
9.3. Fisher Clinical Services, Inc.
9.4. CLINICAL SUPPLIES MANAGEMENT HOLDINGS, INC.
9.5. Xerimis
9.6. PCI Services
9.7. Quay Pharma
9.8. Bilcare Ltd
9.9. August Faller GmbH & Co. KG
9.10. Lonza Group Ltd.
9.11. Rhenochem AG
9.12. Mikart, LLC
